Market Reports /
by Katrina Bullock -
4 years ago
03 Feb 2020 - The Australian marked tumbled today as the coronavirus continues to unsettle international markets causing investors to divest from oil, gas and travel stocks. The AS…
Company News /
by Katrina Bullock -
4 years ago
03 Feb 2020 - A subsidiary of Invion (ASX:IVX), EpiTech Dermal Science, has signed an R&D services agreement with a leading China-based pharmaceutical group in the skin repair and …
Company News /
by Anna Napoli -
5 years ago
16 Jan 2019 - Cancer therapy developer, Invion (ASX:IVX) has strengthened its scientific advisory board appointing experts in skin, lung and prostate cancer.
Company News /
by Rachael Jones -
6 years ago
27 Sep 2018 - Chronic Airway Therapeutics, a proposed spin-off from Invion (ASX:IVX) has selected leading Chinese contract research organisation R&G Pharma Studies Co to support th…
Market Reports /
by Kathy Skantzos -
6 years ago
19 Feb 2018 - The market rose steadily throughout the day due to stronger-than-expected half yearly results. Helloworld Travel (ASX:HLO) reports a 39 per cent increase in profit be…
Market Reports /
by -
9 years ago
02 Nov 2015 - Aus shares close 1.41% lower. Invion Limited (ASX:IVX) has advised the market of completion of enrolment in its phase 2 clinical trial of INV102 in patients with mil…
Market Reports /
by -
10 years ago
24 Sep 2014 - Aus shares reverse gains. eBet Limited (ASX:EBT) has restructured its senior management with Tony Toohey moving from CEO to take the role of Deputy Chairmen and Execu…
Company Presentations /
by Carolyn Herbert -
10 years ago
06 Mar 2014 - Invion Limited (ASX:IVX) Managing Director & CEO Greg Collier presents at ASX Spotlight London about the clinical-stage drug development company’s operations.
